跳轉至內容
Merck
  • Identification of drug-specific public TCR driving severe cutaneous adverse reactions.

Identification of drug-specific public TCR driving severe cutaneous adverse reactions.

Nature communications (2019-08-10)
Ren-You Pan, Mu-Tzu Chu, Chuang-Wei Wang, Yun-Shien Lee, Francois Lemonnier, Aaron W Michels, Ryan Schutte, David A Ostrov, Chun-Bing Chen, Elizabeth Jane Phillips, Simon Alexander Mallal, Maja Mockenhaupt, Teresa Bellón, Wichittra Tassaneeyakul, Katie D White, Jean-Claude Roujeau, Wen-Hung Chung, Shuen-Iu Hung
摘要

Drug hypersensitivity such as severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life-threatening. Here, we enroll SCAR patients to investigate the T cell receptor (TCR) repertoire by next-generation sequencing. A public αβTCR is identified from the cytotoxic T lymphocytes of patients with carbamazepine-SJS/TEN, with its expression showing drug/phenotype-specificity and an bias for HLA-B*15:02. This public αβTCR has binding affinity for carbamazepine and its structural analogs, thereby mediating the immune response. Adoptive transfer of T cell expressing this public αβTCR to HLA-B*15:02 transgenic mice receiving oral administration of carbamazepine induces multi-organ injuries and symptoms mimicking SCAR, including hair loss, erythema, increase of inflammatory lymphocytes in the skin and blood, and liver and kidney dysfunction. Our results not only demonstrate an essential role of TCR in the immune synapse mediating SCAR, but also implicate potential clinical applications and development of therapeutics.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
山羊抗人IgG抗体,Fc, 2 mg/mL, Chemicon®